SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a massive surge as investors react to a significant earnings beat and raised guidance that validates the company's aggressive turnaround strategy and AI data center growth. The stock's parabolic move has sparked intense community debate, with bulls celebrating a long-awaited comeback while shorts face extreme pressure amidst intense speculation over potential squeezes and institutional rotation into the semiconductor sector.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors react to the appointment of a new CEO for the Tanbreez project and a significant consolidation of ownership in the Greenland asset. The community is actively debating the stock's potential as a strategic rare earth supplier, with intense discussion around current short-selling dynamics, squeeze potential, and institutional confidence following the recent capital raise.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc. is experiencing extreme volatility and heavy retail interest following a major legal victory against Papaya Gaming, where a jury awarded the company hundreds of millions in damages with further potential disgorgements pending. While bulls are anticipating a massive short squeeze similar to past momentum plays, the community remains divided between those expecting a continued rally toward triple digits and skeptics who are wary of potential dilution or difficulties in actualizing the legal settlement.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is experiencing intense volatility and aggressive downward pressure, with the community actively debating whether the stock is undergoing a post-squeeze structural collapse or setting up for a potential bounce. Investors are closely monitoring elevated options flow and high short interest, while expressing concerns about the stock's massive two-day retreat from its previous highs.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging in sympathy with Intel's earnings beat and upbeat guidance, as investors rotate into CPU-focused semiconductor names that are seen as critical infrastructure for the expanding AI data center market. The community is sharply divided between bulls riding the aggressive price momentum and bears sounding alarms over extreme valuation levels and the stock's overbought RSI technical indicators.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending following the overwhelming shareholder approval of its massive merger with Warner Bros. Discovery, a move seen as a major consolidation in the media industry to better compete with streaming rivals. While many investors are optimistic about the long-term potential of the combined assets and debt reduction, community discussions remain divided due to concerns over regulatory scrutiny, executive compensation packages, and the impact of consolidation on creative talent.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing a sharp rally driven by investor optimism surrounding its strategic pivot into producing in-house AI-focused CPUs to power enterprise data centers. The community is actively debating the stock's valuation and long-term trajectory as it shifts from a traditional licensing model to a direct hardware competitor.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community rallies around its potential for long-term utility and its increasing alignment with XRP, fueled by anticipation for upcoming industry events. Investors are actively debating the impact of the token's deflationary model while holding strong against volatility, with many optimistic that strategic partnerships and institutional adoption will drive significant growth.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is trending following record-breaking fourth-quarter financial results that significantly exceeded analyst expectations, highlighted by surging revenue and profitability driven by heavy AI infrastructure demand. The community is actively discussing a potential short squeeze due to high short interest, while investors weigh the company's deepening partnership with Dell Technologies against broader market volatility and questions regarding long-term revenue guidance.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The Other segment includes DLP products, calculators, and custom application-specific integrated circuits products. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending following a massive earnings beat and guidance raise, with traders and options activity signaling strong confidence in its role in the AI data center buildout. Investors are actively discussing the stock's parabolic move and its significant industrial and automotive exposure, though some are expressing caution regarding potential overextension and broader market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Grows By 19.4%

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 16,157,271 shares, an increase of 19.4% from the March 15th total of 13,534,910 shares. Approximately 18.1% of the...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the firm...

C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies

C4 Therapeutics partners with Roche to develop cancer-fighting DACs. CCCC eligible for $1B+ in milestones plus royalties. See the details.read more...

<ul class="summary-bullets"><li>C4&nbsp;Therapeutics is also eligible to earn tiered royalties on future product sales.</li><li>C4 and Roche will focus on developing emerging cancer treatments using degrader-antibody conjugates and targeted protein degradation processes.</li><li>The companies will work together on two programs to develop the new cancer treatments.&nbsp;</li></ul>Shares of C4 Therapeutics, Inc. (CCCC) reversed pre-market gains to edge 2% lower on Thursday, after the company expanded its partnership with Swiss pharmaceutical company Roche to develop cancer treatments.C4 Therapeutics said the new collaboration will focus on developing emerging cancer treatments using&nbsp;a degrader-antibody conjugate (DAC) and targeted protein degradation (TPD) processes.&nbsp;“Our new collaboration leverages C4T’s ability to design highly catalytic and selective degraders, as well as degrader payloads for DACs, alongside Roche’s extensive experience developing ADCs with specific binding. Together, these capabilities build a powerful new modality that can offer transformative medicines for patients,” said Andrew Hirsch, President and CEO of C4 Therapeutics.<h2 class="st-heading-2">C4 Could Earn Up To $1 Billion</h2>The companies will work together on two programs to develop new cancer treatments. C4&nbsp;Therapeutics&nbsp;will design the drug components using its TORPEDO platform, which uses advanced tools and AI to target harmful proteins.&nbsp;&nbsp;Roche will create the antibodies and combine them with the drug. Roche will also handle testing, development, and sales.&nbsp;C4&nbsp;Therapeutics&nbsp;will receive a $20 million upfront payment for the two programs, with the potential for additional payments if Roche opts to include a third target. The agreement also includes near-term discovery milestones, while total milestone payments could exceed $1 billion. Additionally, the firm is eligible to earn tiered royalties on future product sales.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the reversal after the opening bell, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/CCCC">CCCC</a> flipped to ‘extremely bullish’ from&nbsp; ‘bearish’ a day earlier, amid ‘high’ message volumes.One user said that, based on the contract, the stock should be around $4 to $5. It is currently around $2.8.<stembedurl>https://stocktwits.com/intrader/message/649802478</stembedurl>Another bullish user highlighted the company’s runway until 2028.<stembedurl>https://stocktwits.com/intrader/message/649810594</stembedurl>The stock has shot up more than 35% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CCCC Stock Reverses Pre-Market Gains After Roche Tie-Up To Develop Cancer Treatments - Retail Sees Strong Upside

Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments.

Equity

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 13,534,910...

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to their sector so far this year.

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have been given an average rating of "Moderate Buy" by the seven ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have i...

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling...

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab

C4 Therapeutics (NASDAQ:CCCC) outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays' 28th Annual Global Healthcare Conference, highlighting...

C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference

C4 Therapeutics (NASDAQ:CCCC) used a presentation at TD Cowen's 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program...

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Current Price	$2.97
Prev Close	$3.07
Open	$3.04
Dividend Yield	0.00%
50-Day Moving Average	$2.68
Beta	1.96
Avg. Volume	2.71M
PE Ratio	-2.19

52-Week High	$3.82
52-Week Low	$1.21
Market Capitalization	$299.56M
EPS (Annual)	-$1.27
Price to Book	1.12
Revenue Per Employee	$345,644.23

CCCC
C4 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CCCC News

CCCCC4 Therapeutics Inc